BACKGROUND: Many studies have suggested that elderly patients are at increased risk of bleeding during heparin therapy. OBJECTIVE: To establish whether the risk of bleeding in the elderly results from concomitant risk factors or is associated with the aging process itself. METHODS:One hundred ninety-nine patients who presented with proximal deep vein thrombosis were treated with a standard intravenous heparin protocol in a double-blind, randomized, prospective study. Bleeding complications were monitored. Activated partial thromboplastin times and heparin levels were assessed 4 to 6 hours after a standard intravenous heparin bolus and infusion. Heparin doses and heparin levels were also assessed after stable therapeutic heparin infusion rates were established. RESULTS: There was an increase in total and major bleeding complications with aging (P < .05) that was not accounted for by standard risk factors for bleeding. Aging was associated with an increase in heparin levels (r = .239, P = .003) and a tendency for an increase in activated partial thromboplastin time (r = .134, P = .07) after standard heparin doses. Aging was also associated with lower heparin dose requirements (r = .267, P = .003) after therapeutic activated partial thromboplastin times were achieved. CONCLUSION: Aging is a risk for heparin-related bleeding that may be explicable by age-related changes in the pharmacologic characteristics of heparin.
RCT Entities:
BACKGROUND: Many studies have suggested that elderly patients are at increased risk of bleeding during heparin therapy. OBJECTIVE: To establish whether the risk of bleeding in the elderly results from concomitant risk factors or is associated with the aging process itself. METHODS: One hundred ninety-nine patients who presented with proximal deep vein thrombosis were treated with a standard intravenous heparin protocol in a double-blind, randomized, prospective study. Bleeding complications were monitored. Activated partial thromboplastin times and heparin levels were assessed 4 to 6 hours after a standard intravenous heparin bolus and infusion. Heparin doses and heparin levels were also assessed after stable therapeutic heparin infusion rates were established. RESULTS: There was an increase in total and major bleeding complications with aging (P < .05) that was not accounted for by standard risk factors for bleeding. Aging was associated with an increase in heparin levels (r = .239, P = .003) and a tendency for an increase in activated partial thromboplastin time (r = .134, P = .07) after standard heparin doses. Aging was also associated with lower heparin dose requirements (r = .267, P = .003) after therapeutic activated partial thromboplastin times were achieved. CONCLUSION: Aging is a risk for heparin-related bleeding that may be explicable by age-related changes in the pharmacologic characteristics of heparin.
Authors: Juliessa M Pavon; Richard J Sloane; Carl F Pieper; Cathleen S Colón-Emeric; Harvey J Cohen; David Gallagher; Miriam C Morey; Midori McCarty; Thomas L Ortel; Susan N Hastings Journal: J Hosp Med Date: 2018-02-06 Impact factor: 2.960
Authors: Sabin S Egger; Andrea Bachmann; Nathalie Hubmann; Raymond G Schlienger; Stephan Krähenbühl Journal: Drugs Aging Date: 2006 Impact factor: 3.923
Authors: Frederick A Spencer; Joel M Gore; Darleen Lessard; Cathy Emery; Luigi Pacifico; George Reed; Jerry H Gurwitz; Robert J Goldberg Journal: Thromb Haemost Date: 2008-11 Impact factor: 5.249
Authors: Frederick Leri; Stephen J Voyce; Salvatore Scialla; William Glavich; Edward Dzielak; Raymond A Smego; John Guzek Journal: J Thromb Thrombolysis Date: 2009-03-13 Impact factor: 2.300